The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:
As part of the FDA's effort to protect consumers, on Sept. 28, the agency issued a warning letter to Strategia Project Management, Inc. for selling an unapproved product with unproven COVID-19 claims. Consumers concerned about COVID-19 should consult with their health care provider.
Testing updates:
As of today, 414 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 289 molecular tests and sample collection devices, 89 antibody and other immune response tests and 36 antigen tests. There are 65 molecular authorizations and one antibody authorization that can be used with home-collected samples. There is one molecular prescription at-home test, three antigen prescription at-home tests, eight antigen over-the-counter (OTC) at-home tests and two molecular OTC at-home tests.
The FDA has authorized 16 antigen tests and eight molecular tests for serial screening programs. The FDA has also authorized 641 revisions to EUA authorizations.
This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA
Post a Comment
Post a Comment